TORC resTORbio Inc.

1.41
-0.05  -3%
Previous Close 1.46
Open 1.49
Price To Book 0.47
Market Cap 51,385,520
Shares 36,443,631
Volume 2,786,732
Short Ratio
Av. Daily Volume 2,475,293
Stock charts supplied by TradingView

NewsSee all news

  1. resTORbio to Present at Upcoming Investor Conferences

    BOSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related

  2. resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint

    -- Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in other aging-related diseases, including Parkinson's disease -- -- Company remains well

  3. resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update

    Top-line data from PROTECTOR 1 study expected by early first quarter of 2020 RTB101 Phase 2b data demonstrating upregulation of innate antiviral immunity presented at IDWeek™ 2019 BOSTON, Nov. 05, 2019 (GLOBE

  4. AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP

    WALTHAM, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) ("AMAG") today announced that it has entered into a settlement agreement with Caligan Partners LP ("Caligan"). As part of this

  5. resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

    BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data did not meet primary endpoint - November 15, 2019.
RTB101 - PROTECTOR 1
Respiratory Tract Infections
Phase 2 data due 2020.
RTB101
Parkinson's disease
Phase 2b data presented at IDSA October 3, 2019.
RTB101
Respiratory Tract Infections

Latest News

  1. resTORbio to Present at Upcoming Investor Conferences

    BOSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related

  2. resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint

    -- Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in other aging-related diseases, including Parkinson's disease -- -- Company remains well

  3. resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update

    Top-line data from PROTECTOR 1 study expected by early first quarter of 2020 RTB101 Phase 2b data demonstrating upregulation of innate antiviral immunity presented at IDWeek™ 2019 BOSTON, Nov. 05, 2019 (GLOBE

  4. AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP

    WALTHAM, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) ("AMAG") today announced that it has entered into a settlement agreement with Caligan Partners LP ("Caligan"). As part of this

  5. resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

    BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related

  6. resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related

  7. resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019

    BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (NASDAQ:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related